Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Launched by WESTERN INSTITUTE FOR VETERANS RESEARCH · Nov 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying whether the human papillomavirus (HPV) vaccine can help treat stubborn skin warts that have not responded to other treatments. Participants in the trial will be randomly assigned to receive either the HPV vaccine or a placebo, which is an inactive substance that looks like the vaccine but doesn’t have any active ingredients. The goal is to see if the vaccine can effectively reduce or eliminate these warts.

To be eligible for this trial, participants must be at least 18 years old and have a clinical diagnosis of cutaneous warts, meaning warts that appear on the skin. They should have also tried other treatments for their warts before, such as freezing, scraping, or using medicated creams. However, people with untreated warts, certain types of warts in other areas of the body, or those who have been sick recently cannot participate. If you join the trial, you will receive either the vaccine or the placebo, but neither you nor the researchers will know which one you got until the study is finished. This helps ensure the results are fair and unbiased.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Must be able to understand and provide written informed consent
• • 2. Age 18 or older
• • 3. Clinical diagnosis of cutaneous warts
• • 4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)
• Exclusion Criteria:
• • 1. Untreated cutaneous warts
• • 2. Anogenital warts
• • 3. Oral warts
• • 4. Treatment for cutaneous warts in the past 4 weeks
• • 5. Active acute illness
• • 6. Immunosuppression
• • 7. Known hypersensitivity to HPV vaccination
• • 8. Subjects may not receive any other investigational treatment
• • 9. Pregnancy or planned pregnancy during the study period